^
Association details:
| Biomarker: | CCNE1 amplification |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
Excerpt:
...- Patients must have one of the histologically advanced solid tumors harboring CCNE1 amplification: Their diseases are refractory to, or do...
Trial ID:
Source:
Title:
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Published date:
12/05/2022
Excerpt:
Patients aged ≥ 18 years with measurable disease and refractory solid tumors harboring CCNE1 amplification...were studied....Eight patients had partial responses (PRs), and three had stable disease (SD) ≥ 6 months, with an ORR of 27% (95% CI, 12 to 46), a SD ≥ 6 months/PR rate of 37% (95% CI, 20 to 56), a median progression-free survival duration of 4.1 months (95% CI, 1.8 to 6.4), and a median overall survival duration of 9.9 months (95% CI, 4.8 to 15)....Adavosertib monotherapy demonstrates a manageable toxicity profile and promising clinical activity in refractory solid tumors harboring CCNE1 amplification...
DOI:
10.1200/JCO.22.00830
Trial ID:
